• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

4 Biotechs Set to Provide a Shot in the Arm

Each company has approaching catalysts.
By BRET JENSEN
Sep 09, 2016 | 10:24 AM EDT
Stocks quotes in this article: NVAX, DVAX, AERI, KMDA, SHPG

Bret Jensen is a regular contributor to Real Money Pro. Click here to learn about this dynamic market information service for active traders.

The biotech sector has had a nice few days this holiday-shortened trading week, beating the S&P 500 every day. And I believe sentiment should start to improve on both the pharma and biotech groups after the upcoming election likely results in a continued divided government.

Amid this backdrop, there are several smaller names in the lucrative, but volatile small biotech/biopharma to consider. Each have approaching catalysts.

Let's start with Novavax (NVAX) , which is starting to make a nice little move. This vaccine play has a large-scale Phase III trial around a promising respiratory syncytial virus (RSV) vaccine whose results should be out by the end of the month. It may not have the current notoriety of the Zika virus, but RSV hospitalizes more than 200,000 elderly individuals in the U.S. every year.

Next up, there is Dynavax Technologies (DVAX) , which sold off last week as the Ad Comm panel around its hepatitis B vaccine "Heplisav-B" was unexpectedly cancelled. The stock has recovered somewhat this week after the company issued a statement clarifying that event and the mid-December PDUFA date with the FDA seems fully in place.

It is hard to see how this vaccine does not get approved given the far-superior results it delivered compared to the current standard on the market, in a more-than-10,000-person Phase 3 trial. Several analyst firms have chimed in this week to support that view.

Given Dynavax has a market capitalization of less than $500 million and almost $150 million in cash on its balance sheet, the stock should go much higher on approval.

I recently took a small position in ocular concern Aerie Pharmaceuticals (AERI) . The company just filed its first new drug application (NDA) for its first product to treat glaucoma, which looks headed to commercialization. If all goes well, that compound could be on the market in the first half of 2017.

Aerie also has a second drug in the pipeline that is about a year behind its first. As for the stock, a beneficial owner recently made a purchase of more than $4 million, and the shares seem undervalued, with the company's market capitalization at less than $600 million.

Finally, I picked up a few shares in a thinly traded Israeli based biopharma, Kamada (KMDA) , this week. The company just filed a Biologic License Application (BLA) for its post-exposure rabies treatment, a human anti-rabies immune globulin. If approved, it will be marketed with partner Kendrion into a market that is believed to be $100 million annually in the U.S.

The company also has a few products on the market it distributes via other partners, such as Baxalta, which was recently purchased by Shire (SHPG) . It has a good pipeline and sales are increasing some 20% annually.

Kamada should do $75 million to $80 million in revenue this year and $100 million in fiscal year 2017 when it should turn profitable. It has a solid balance sheet and an undervalued $175 million market capitalization.
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jensen was long AERI, DVAX, KMDA and NVAX.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

2 Stocks That Should Perform Well Even if Consumers Pull In Their Horns

Bret Jensen
Aug 17, 2022 10:00 AM EDT

There are reasons to be optimistic about Hims & Hers Health and OptiNose Inc.

There Are Market Bright Spots, but I View the July Rally as a Head Fake

Bret Jensen
Aug 3, 2022 10:30 AM EDT

It's hard to see stock valuations rising when inflation remains high and the economy appears headed for a recession if it isn't in one already.

A Recession Appears Inevitable, but There Are Still Places to Invest

Bret Jensen
Jul 27, 2022 10:30 AM EDT

A few homebuilders and healthcare stocks seem likely to hold up better than most of the market in a recession.

Change Healthcare Continues to Knock on a Breakout Level

Bruce Kamich
Jul 25, 2022 11:25 AM EDT

The CHNG chart is at an interesting juncture.

The Healing Process Begins for Cano Health

Bruce Kamich
Jul 21, 2022 1:30 PM EDT

Here's how to approach CANO as the shares have made a bottom formation.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:23 PM EDT STEPHEN GUILFOYLE

    We're Cleaning Out This Retailer From the Bullpen

    Check out the latest moves in TheStreet's Stocks U...
  • 10:24 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    To Improve Your Trading and Investing, Spend More ...
  • 08:44 AM EDT PETER TCHIR

    CPI Beats Expectations, But Maybe Not the 'Whisper'?

    Slightly better-than-expected inflation across the...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login